11 July 2018
Consultancy Eignapharma, member of CataloniaBio & HealthTech, has reached a collaboration agreement with Biogem, an Italian consortium specialised in lab scale development and production of biosimilars, monoclonal antibodies, new biological entities and related preclinical studies.
Under this agreement Eignapharma will use its commercial efforts to put at the industry disposal Biogem’s research and development capabilities consisting on documented small-scale processes and fully protocolised technology transfers procedures to allow a safe scaleup to industrial production.
Biogem is conformed by the Italian National Research Council (CNR),the Area Science Park of Trieste, the University of Naples "Federico II", the University of Milano ...
11 July 2018
The biomedicine, innovative medical technology and health ecosystem in Catalonia is maturing and there are more and more companies that experience the full business cycle through to success. Licensing deals, selling the company or commercialising the product in different markets are the main paths to this promised land.
Palobiofarma, STAT-Dx and NEOS Surgery are good examples. CataloniaBio & HealthTech invited their founders and general managers to the Lessons Learned debate forum, on 4 July at the Barcelona Science Park (PCB) to share their experiences and the lessons they've learned with new start-ups and spin-offs. The session ...
10 July 2018
The Spanish Bioindustry Association (Asebio) presented the Asebio Report 2017 with the latest data on the Spanish biotechnology sector on 9 July in Madrid.
One of the most noteworthy figures is the investment raised, €150 million, up 17% from 2016. Also, the sector's impact on the economy as a whole, generating 7.8% of the GDP and 108,000 jobs.
9 July 2018
Biopharmaceutical firm Spherium Biomed has begun phase-I clinical trials on their product Cilakin to prevent acute kidney failure based on more than 10 yearsof research conducted by Dr Alberto Tejedor and Dr Alberto Lázaro at Hospital Gregorio Marañón in Madrid. Spherium acquired the licence in 2015 in order to develop an injectable drug suitable for patients (more than 3 million cases each year in Europe, the United States and Japan).
"Cilakin could become the first standardised preventative treatment for this condition," explains Dr Montserrat Cano, head ofthe project at Spherium. The mortality rate can be up to 70% in ...
7 July 2018
Dr Jordi Mestres, founder and CEO of CataloniaBio & HealthTech member Chemotargets and coordinator of the Systems Pharmacology Group at the Hospital del Mar Research Institute (IMIM), has been admitted as a fellow of the Royal Society of Chemistry.
This recognition, one of the most important granted to a chemist, is an important milestone in a researcher's career because it is indicative of scientific quality.
The Royal Society of Chemistry has more than 54,000 members around the world and heritage spanning over 175 years. Its mission is to advance the chemical sciences by investing in educating future ...
3 July 2018
Leukos Biotech, spin-off of the Jose Carreras Leukaemia Research Institute supported by Inveready, has received the Food and Drug Administration (FDA) orphan drug designation for its drug candidate LK-01.
LK-01 is a product based on Apomorphine for the treatment of Acute Myeloid Leukemia (AML), a blood cancer arising from the myeloid lineage of haematopoietic stem cells. A still relevant proportion of patients with AML die from progressive disease after relapse.
The potential benefit of LK-01 is being explored in a phase I/II trial in elderly patients and relapsed patients with AML. Results are expected later in 2019.
The US ...
3 July 2018
Banc Sabadell ha obert la nova convocatòria BStartup Health per donar suport a projectes que es trobin en fases inicials de l'àmbit de la salut (dispositius mèdics, salut digital, diagnòstic i terapèutic). Els tres projectes seleccionats rebran 75.000 euros d’inversió i un pla d’acompanyament.
El comitè cientificotècnic està format per Carlos Gallardo, CEO de CG Health Partners i membre del consell d’Almirall; Damià Tormo, soci de Columbus Venture Partners, i Montserrat Vendrell, sòcia d’Alta Life Sciences i membre de la junta de CataloniaBio & HealthTech. A més d'aquest comitè, els projectes se seleccionaran amb el suport de ...
26 June 2018
Bio€quity Europe, the longest investor event for the European biotechnology sector, will take place in Barcelona for the first time on 20th and 21st May 2019. The conference will be held in Barcelona at the initiative of the Host Regional Committee, which brings together Biocat, Ysios Capital, ACCIÓ and CataloniaBio & HealthTech.
Bio€quity Europe —organised by BioCentury and EBD Group— has showcased more than 800 leading European companies and thousands of investment and pharma business development professionals. More than 550 delegates from 26 nations attended latest edition in Ghent.
"Barcelona has all of the key ingredients for a ...
25 June 2018
Almirall launches the open innovation platform AlmirallShare with the aim of finding advanced small molecules that could be used in the therapeutic treatment of atopic dermatitis, psoriasis, acne, actinic keratosis, and related dermatological diseases.
The call is addressed to universities, research centers, biotech companies, start-ups, and pharma companies all over the world with research compounds that have shown good potency and an acceptable pharmacokinetic profile or development compounds that have shown a good human safety profile.
Submitting a proposal is as easy as going to sharedinnovation.almirall.com.
19 June 2018
FreeOx Biotech, spin-out of Hospital Clinic Barcelona-IDIBAPS and member of CataloniaBio & HealthTech, has opened a round of investment hoping to raise €500,000. The company’s goal this year is to accelerate development and the regulatory process for its drug candidate Ox-01, which has completed phase IIb, and begin preclinical trials with Ox-02. Both drugs are being used to treat stroke and other diseases of the central nervous system (CNS).
“We’re looking for a total of €500,000 and we’ve already raised €200,000 from two private investors,” explained Carlos Lurigados, co-founder and CEO of FreeOx. These investors ...